Inhibrx Biosciences (INBX) Other Working Capital Changes (2023 - 2025)
Inhibrx Biosciences (INBX) posted quarterly Other Working Capital Changes of -$535000.0 for Q4 2025, down 664.29% year-over-year from $94810.1 in Q4 2024, and down 2.49% quarter-over-quarter from -$522000.0 in Q3 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Other Working Capital Changes (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Other Working Capital Changes for 3 consecutive years, with -$535000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Working Capital Changes fell 664.29% year-over-year to -$535000.0; the TTM figure through Dec 2025 stood at -$1.6 million (down 13.28% YoY), while the FY2025 annual figure was -$1.6 million, down 13.28% from the prior year.
- Other Working Capital Changes retreated to -$535000.0 in Q4 2025 per INBX's latest filing, from -$522000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $15.1 million in Q3 2023 and bottomed at -$9.0 million in Q4 2023.
- Historically, Other Working Capital Changes has averaged $177200.0 across 3 years, with a median of -$322500.0 in 2025.
- Annual changes were most pronounced in 2024 — Other Working Capital Changes surged 85.54% — and 2025, when it plunged 664.29%.
- Inhibrx Biosciences' Other Working Capital Changes stood at -$484000.0 in 2023, then soared by 85.54% to -$70000.0 in 2024, then slumped by 664.29% to -$535000.0 in 2025.
- Business Quant data shows INBX's Other Working Capital Changes at -$535000.0 in Q4 2025, -$522000.0 in Q3 2025, and -$367000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -535,000.00 |
| Dec 31, 2025 | -535,000.00 |
| Sep 30, 2025 | -108,000.00 |
| Sep 30, 2025 | -108,000.00 |
| Jun 30, 2025 | -222,000.00 |
| Jun 30, 2025 | -222,000.00 |
| Mar 31, 2025 | -730,000.00 |
| Mar 31, 2025 | -730,000.00 |
| Dec 31, 2024 | -1.64 Mn |
| Dec 31, 2024 | -1.64 Mn |
| Sep 30, 2024 | -4.78 Mn |
| Sep 30, 2024 | -4.78 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 2.36 Mn |
| Mar 31, 2024 | 2.36 Mn |
| Dec 31, 2023 | -8.98 Mn |
| Dec 31, 2023 | -8.98 Mn |
| Sep 30, 2023 | 15.14 Mn |
| Sep 30, 2023 | 15.14 Mn |